



Financial Tear Sheet

Corporate Profile

Synta Pharmaceuticals is a biopharmaceutical company focused on discovering, developing, and commercializing novel pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. All clinical candidates were invented internally by Synta scientists using our compound library and discovery capabilities.

Primary IR Contact

Rob Kloppenburg
 VP, Investor Relations & Corporate
 Communications
 Phone: (781) 541-7125
 Fax: (781) 274-1270
 E-mail: ir@syntapharma.com

Stock Performance

SNTA (Common)

Exchange	NASDAQ (US Dollar)
Price	\$3.04
Change (%)	▲ 0.20 (7.04%)
Volume	139,942
52 Week Low	\$2.55
Market Cap	\$123,262,880
Rolling EPS	2.81
PE Ratio	1.0819
Shares Outstanding	40,547,000
Data as of 09/09/10 4:00 p.m. ET	



Recent Headlines & Events

09/08/10 - 8:07 a.m.
 Synta Pharmaceuticals to Present at the Robert W. Baird 2010 Health Care Conference

08/24/10 - 7:02 a.m.
 Synta Announces First Patient Treated in Clinical Trial of STA-9090 in Combination with Docetaxel in Solid Tumors

08/09/10 - 4:26 p.m.
 Synta Pharmaceuticals Reports Second-Quarter 2010 Financial Results and Clinical Update

Date	Title
09/14/10 3:45 p.m. ET	Synta Pharmaceuticals Corp. at Robert W. Baird & Co., Inc. Health Care Conference Location New York, NY

SEC Filings

Filing Date	Form
08/31/10	8-K
08/20/10	4
08/09/10	10-Q
08/06/10	4

Corporate Governance

Safi R. Bahcall, Ph.D.	Director, President and Chief Executive Officer
Michael P. Bailey	Senior Vice President, Business Development and Chief Commercial Officer
Jeremy G. Chadwick, Ph.D.	Senior Vice President, Program Management and Clinical Operations
Keizo Koya, Ph.D.	Senior Vice President, Drug Development
Vojo Vukovic, M.D., Ph.D.	Senior Vice President, Chief Medical Officer
Suresh R. Babu, Ph.D.	Vice President, Drug Product Development
Keith S. Ehrlich, C.P.A.	Vice President, Finance and Administration, Chief Financial Officer
Robert Kloppenburg	Vice President, Investor Relations and Corporate Communications
Arthur J. McMahon	Vice President, Human Resources
Wendy E. Rieder, Esq.	Vice President, Intellectual Property and Legal Affairs General Counsel
Andrew J. Sonderfan, Ph.D., DABT	Vice President, Drug Disposition and Preclinical Safety
Lijun Sun, Ph.D.	Vice President, Chemistry
David Noskowitz	Senior Director, Regulatory Affairs

Ownership Summary

Shareholders				
	Holders	Value (\$MM)	% O/S	Shares
Institution	86	90.85	57.4	23,280,892
Mutual Fund	94	8.74	5.6	2,267,535
Insider *	17	71.55	60.9	24,671,293

* Insider values reflect direct beneficial ownership.

Top Holders				
	Shares Held	% O/S	Share Change	Filing Date
CxSynta, L.L.C.	7,761,716	19.1	0	03/01/10
Chen (Lan Bo)	3,383,452	8.3	-31,000	03/01/10
Bahcall (Safi R)	2,321,586	5.7	36,061	03/01/10
Gollust (Keith R)	1,742,046	4.3	116,806	03/01/10
Kovner (Bruce)	1,500,673	3.7	566,806	03/01/10
AIG Asset Management (U.S.), LLC	1,207,085	3.0	0	06/30/10
BlackRock Institutional Trust Company, N.A.	780,557	1.9	177,269	06/30/10
Wilson (Robert N)	464,677	1.2	108,403	03/01/10
Dimensional Fund Advisors, LP	399,844	1.0	20,049	06/30/10
State Street Global Advisors (US)	356,327	0.9	19,753	06/30/10

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed